Understanding the Market | Chunli Medical rose over 10%, turning a profit of 77.0619 million yuan in the third quarter as the company actively expands its international market business
CHUNLI MEDICAL's stock price rose by more than 10%, with an increase of 10.66% as of the time of publication, reported at HKD 18.37, with a transaction volume of HKD 45.461 million. The company released its performance for the first three quarters of 2025, with operating revenue of 756 million yuan, a year-on-year increase of 48.75%; net profit attributable to the parent company of 192 million yuan, a year-on-year increase of 213.21%. In the third quarter, it achieved operating revenue of 268 million yuan, a year-on-year increase of 109.51%; net profit attributable to the parent company of 77.0619 million yuan, turning a profit. Huatai Securities pointed out that the company is actively expanding its international market, with rapid growth in overseas revenue, which has become an important source of income
According to Zhitong Finance APP, Chunli Medical (01858) rose over 10%, with a current increase of 10.66%, priced at HKD 18.37, with a transaction volume of HKD 45.461 million.
In terms of news, Chunli Medical released its performance for the first three quarters of 2025, reporting an operating income of RMB 756 million, a year-on-year increase of 48.75%; the net profit attributable to shareholders of the listed company was RMB 192 million, a year-on-year increase of 213.21%. In the third quarter alone, the company achieved an operating income of RMB 268 million, a year-on-year increase of 109.51%; the net profit attributable to the parent company was RMB 77.0619 million, turning a profit from a loss compared to the same period last year.
Huatai Securities believes that the company's rapid year-on-year growth in the third quarter is mainly due to its steady progress in expanding international markets, continuous growth in export business revenue, and increased sales of centralized procurement products, with a positive outlook for sustained rapid growth in overseas revenue. The firm pointed out that the company is actively expanding its international market business, with overseas revenue growing rapidly, which has become an important source of income. The company's hip, knee, and spine product series have all successfully passed the CE annual system audit and supervision audit, and the knee prosthesis system has received FDA 510(K) approval in the United States, indicating that the company's technological advantages have reached an internationally leading level, providing strong competitiveness in the international market and laying a foundation for the continuous increase in the company's international sales
